title: Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting.
abstract: Saphenous vein coronary artery bypass graft patency can be increased by antiplatelet therapy. Aspirin plus dipyridamole are effective but are associated with tolerability problems. Indobufen is a possible alternative antiplatelet agent that may be better tolerated. A prospective, randomized, double-blind, parallel-group study was undertaken to compare the efficacy and safety of indobufen 200 mg twice daily with aspirin 300 mg thrice daily plus dipyridamole 75 mg thrice daily in preventing occlusion of autologous saphenous vein coronary artery bypass grafts. A total of 803 patients were randomized in the study, of whom 552 had a follow-up coronary angiogram approximately 1 year after operation. All anastomoses were patent in 56% of indobufen-treated patients and 59% of aspirin-dipyridamole recipients (p = 0.384). The percentage of all anastomoses patent was 82% in the indobufen group and 83% in the aspirin-dipyridamole group (p = 0.297). Mean postoperative blood loss was significantly less in the indobufen group (p = 0.043). Patients who received indobufen also had significantly fewer adverse events considered to be treatment-related compared with aspirin-dipyridamole recipients (p = 0.02). At the doses tested indobufen was as effective as aspirin plus dipyridamole in preventing occlusion of saphenous vein grafts and was better tolerated. Because indobufen was associated with less postoperative blood loss it may be used before operation in coronary artery bypass grafting.
authors.affiliation: Killingbeck Hospital, Leeds, United Kingdom.
authors.forename: S M
authors.initials: SM
authors.lastname: Rajah
authors.forename: U
authors.initials: U
authors.lastname: Nair
authors.forename: M
authors.initials: M
authors.lastname: Rees
authors.forename: N
authors.initials: N
authors.lastname: Saunders
authors.forename: D
authors.initials: D
authors.lastname: Walker
authors.forename: G
authors.initials: G
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Critchley
authors.forename: D
authors.initials: D
authors.lastname: Beton
authors.forename: C
authors.initials: C
authors.lastname: Campbell
authors.forename: R A
authors.initials: RA
authors.lastname: Lawson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011182:Postoperative Care / Q000706:statistics & numerical data; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; C020371:indobufen; D001241:Aspirin